Reventa 70mg Tablet

Description

Reventa 70mg Tablet

Reventa 70mg Tablet (Alendronate sodium) is an aminobisphosphonate that acts as a potent inhibitor of bone resorption. Reventa 70mg Tablet is chemically described as (4-amino-1- hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate. Reventa 70mg Tablet molecular formula is C4H12NNaO7P2•3H2O. Estrogen/Hormone Replacement Therapy (HRT) Combined use of alendronate and HRT resulted in greater increases in bone mass, together with greater decreases in bone turnover, than seen with either treatment alone. The safety and tolerability profile of the combination was consistent with those of the individual treatments. Calcium Supplements/Antacids Reventa 70mg Tablet is likely that calcium supplements, antacids, and some oral medications will interfere with absorption of alendronate. Therefore, patients must wait at least one-half hour after taking alendronate before taking any other oral medications. Aspirin The incidence of upper gastrointestinal adverse events increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10mg and aspirin-containing products. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Since NSAID use is associated with gastrointestinal irritation, caution should be used during concomitant use with alendronate.

Uses

In postmenopausal women for the treatment of osteoporosis to prevent fractures, including those of the hip and spine (vertebral compression fractures). l In postmenopausal women who are at risk of developing osteoporosis. l For the treatment of osteoporosis in men to prevent fractures. l For the treatment and prevention of glucocorticoid-induced osteoporosis in men and women. l For the treatment of Paget’s disease of bone in men and women.

Side effect :

Common: Hypersensitivity reactions including urticaria, transient symptoms of myalgia and malaise. Rare: Angioedema, fever, symptomatic hypocalcemia. Gastrointestinal: Common: Esophagitis, esophageal erosions, esophageal ulcers. Rare: Esophageal stricture or perforation and oropharyngeal ulceration

When not use :

– Hypersensitivity to any component of this product. – Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia. – Inability to stand or sit upright for at least 30 minutes. – Hypocalcemia.